Clinical trial Recruiting at 1 site Observational

Surgical techniques and outcomes across the lifespan in congenital heart disease in China

Official title: Evaluation of Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease Based on a Chinese Multicenter Database

Run by China National Center for Cardiovascular Diseases · NCT07524998 · Data updated 2026-11-12

See which surgical factors and care patterns affect recovery after heart surgery for people with complex congenital heart disease in China.

More Congenital Heart Disease trials

Quick facts

Study typeObservational
SexAll
Enrollment3000 (estimated)
SponsorChina National Center for Cardiovascular Diseases
Government
Locations1 site (Beijing)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedJanuary 31, 2029
Study endsJanuary 31, 2029
Registry record updatedApril 13, 2026
Trial IDNCT07524998 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People with complex congenital heart disease who have undergone or plan to undergo cardiac surgery at a participating center and who can provide informed consent and complete follow-up.

Probably not a fit

Patients with severe extracardiac malformations or systemic dysfunction that preclude participation, those lost to follow-up, or those with large amounts of missing core clinical data may not benefit from the study's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational project will enroll people with complex congenital heart disease (CCHD) who have had or will have cardiac surgery at participating Chinese centers, combining retrospective cases from the national database with prospective follow-up. Investigators will collect clinical, surgical, perioperative, and longitudinal outcome data and integrate them into a multi-dimensional, life-course data platform. The dataset will be analyzed to identify main risk factors for postoperative recovery and to develop China-specific quality control metrics for CCHD surgical care. Results are intended to guide clinical quality improvement and inform national health policy.

Why it matters

Potential benefit: If successful, this could produce China-specific surgical quality standards and care pathways that reduce complications and improve long-term outcomes for people with CCHD.

How similar studies have gone: Large congenital cardiac surgical registries and quality collaboratives elsewhere (for example, the STS congenital database) have led to measurable improvements, but a China-specific, life-course CCHD data platform is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical diagnosis of Complex Congenital Heart Disease (CCHD) who underwent surgical intervention and were enrolled in the 13th Five-Year Plan National Congenital Heart Disease Surgery Database
* Clinical diagnosis of CCHD requiring surgical/intrauterine intervention or cardiac rehabilitation
* Willing to sign informed consent and complete follow-up

Exclusion Criteria:

* Lost to follow-up
* \>30% missing core clinical data
* Severe extracardiac malformations, systemic dysfunction, or other conditions precluding study participation, per sub-study specific exclusion criteria

Where it's running

  • Fuwai Hospital, Chinese Academy of Medical Science, PUMC
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.